Plain-English translation of NCT07751042 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new medication called that is given through an IV (intravenous infusion) to treat advanced cancers. The researchers want to see if this medication works better when given by itself or when combined with pembrolizumab, a drug that helps your immune system fight cancer. This is the first time is being tested in people, so the study will carefully monitor its safety and how well it works.
Many patients with advanced cancers like melanoma and lung cancer have limited treatment options, especially after standard therapies stop working or cause side effects they cannot tolerate. This medication is being tested to offer a new hope for these patients by potentially harnessing the body's immune system to fight cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the medication once per treatment cycle, with each cycle lasting about 3 weeks, for up to 35 cycles (approximately 24 months). Depending on which arm of the study you are assigned to, you may receive the new medication alone or in combination with pembrolizumab. You will have regular blood tests, imaging scans, and medical visits to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States